Nanotechnology Now - Press Release: New data highlighting ABRAXANE as single agent and in combination for the treatment of breast, lung and ovarian cancers to be presented at ASCO

Home > Press > New data highlighting ABRAXANE as single agent and in combination for the treatment of breast, lung and ovarian cancers to be presented at ASCO

Abstract:
Abraxis BioScience, Inc. (NASDAQ: ABBI), an integrated, global biopharmaceutical company, today announced that multiple studies of ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound
particles for injectable suspension) (albumin bound) will be presented at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, June 1-5, 2007. Data will be presented from studies which highlight the potential utility of ABRAXANE (ABI-007) as a single-agent and in
combination for the treatment of breast, lung and ovarian cancers.

New data highlighting ABRAXANE as single agent and in combination for the treatment of breast, lung and ovarian cancers to be presented at ASCO

LOS ANGELES, CA | Posted on May 30th, 2007

An updated analysis of the study titled "A Randomized Phase II Study of
Weekly or Every 3 Weeks ABI-007 vs. Every 3 Weeks Taxotere(R) as First Line
Therapy of Stage IV Metastatic Breast Cancer" (Abstract 1032) will be
presented as a poster on Saturday, June 2, 2007 from 8 a.m. to 12 p.m
(Room S403), with a poster discussion following from 12 p.m. to 1 p.m., S406
(Vista Room). The updated analysis of the Phase II study evaluates first-line
treatment ABRAXANE given weekly and every three weeks compared to Taxotere(R)
(docetaxel) dosed every three weeks in patients with metastatic breast cancer.
Interim results of this study were presented at the San Antonio Breast Cancer
Symposium in December 2006.
Abraxis is continuing to expand its clinical experience with ABRAXANE and
its potential in treating multiple tumor types as a single agent and in
combination. Data from company and investigator-sponsored studies in breast,
lung and ovarian cancer will be presented during the poster presentations
including:

BREAST CANCER
-------------

Randomized study comparing nab-paclitaxel with solvent-based paclitaxel
in Chinese patients (pts) with metastatic breast cancer (MBC) (Abstract 1038)
Poster Presentation: Saturday, June 2, 8:00 a.m. to 12:00 p.m., Room S403
Poster Discussion: Saturday, June 2, 12 p.m. to 1 p.m., Room S406 (Vista
Room)

NCCTG Phase II trial N0531of weekly nab-paclitaxel (nab-p) in combination
with gemcitabine (gem) in patients with metastatic breast cancer (MBC)
(Abstract 1048)
Poster Presentation: Saturday June 2, 2 p.m. to 6 p.m., S Hall A2

Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel
(ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast
cancer (MBC): Interim Results (Abstract 1053)
Poster Presentation: Saturday June 2, 2 p.m. to 6 p.m., S Hall A2

Randomized phase II trial of three dosing schedules of nanoparticle
albumin-bound paclitaxel with bevacizumab as 1st-line therapy for HER2
negative metastatic breast cancer: An initial interim safety report (Abstract
1104)
Poster Presentation: Saturday June 2, 2 p.m. to 6 p.m., S Hall A2

LUNG CANCER
-----------

Study of three weekly nab-paclitaxel regimens in combination with
carboplatin as first line therapy in advanced non-small cell lung cancer
(NSCLC) (Abstract 7659)
Poster Presentation: Sunday June 3, 8 a.m. to 12 p.m., S Hall A2

An open-label, Phase II trial of nanoparticle albumin bound paclitaxel
(nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with
advanced non-squamous non-small cell lung cancer (NSCLC) (Abstract 7610)
Poster Presentation: Sunday, June 3, 8 a.m. to 12 p.m., S Hall A2

OVARIAN CANCER
--------------

Results of a Phase II evaluation of nanoparticle albumin bound paclitaxel
(nab-paclitaxel) in platinum-sensitive patients with recurrent ovarian,
peritoneal, or fallopian tube cancer (Abstract 5525)
Poster Presentation: Sunday, June 3, 8 a.m. to 12 p.m., Room E451a
Poster Discussion: Sunday, June 3, 11 a.m. to 12 p.m., Room E354a

####

About Abraxis BioScience, Inc.
Abraxis BioScience, Inc. is an integrated global biopharmaceutical
company dedicated to meeting the needs of critically ill patients. The company
develops, manufactures and markets one of the broadest portfolios of
injectable products and leverages revolutionary technology such as its nab(TM)
platform to discover and deliver breakthrough therapeutics that transform the
treatment of cancer and other life-threatening diseases. The first FDA
approved product to use this nab platform, ABRAXANE(TM), was launched in 2005
for the treatment of metastatic breast cancer. Abraxis trades on the NASDAQ
Stock Market under the symbol ABBI. For more information about the company and
its products, please visit http://www.abraxisbio.com .
Taxotere(R) is a registered trademark of Sanofi-Aventis.

About ABRAXANE(TM)

ABRAXANE(TM) for Injectable Suspension (paclitaxel powder for injectable
suspension) (nanoparticle, albumin-bound (nab(TM)) paclitaxel) received
approval in June 2006 from the Therapeutic Products Directorate of Health
Canada under a Notice of Compliance for the treatment of metastatic breast
cancer in Canada. Canada is the first major commercial market to grant an
approval for ABRAXANE(TM) that includes first-line treatment of metastatic
breast cancer. The U.S. Food and Drug Administration approved ABRAXANE(TM) in
January 2005.

About Abraxis Oncology

Abraxis Oncology, a wholly owned division of Abraxis BioScience Inc., is
devoted to the global development and commercialization of next generation
cancer therapies. The Canadian affiliate of Abraxis Oncology is located in
Richmond Hill, Ontario. For more information about the division and its
products, please visit http://www.abraxisoncology.com .